All In Biotech

Drug Trial Radar · NCT06666179

Safety and Immunogenicity Study of SCB-1019T in Children

A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Reactogenicity and Immunogenicity of a Bivalent Recombinant RSV Vaccine (SCB-1019T) in Children 2 to <6 Years of Age

Last checked: Nov 20, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Oct 2025

Primary completion

Jun 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Oct 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 24 months, up to 71 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase 1 study in Australia will evaluate the safety, reactogenicity and immunogenicity of the Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T) in children 2-\<6 years of age.

Conditions

  • RSV Infection

Interventions

  • low dose SCB-1019TBiological

    Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)

  • adjuvanted low dose SCB-1019TBiological

    Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)

  • high dose SCB-1019TBiological

    Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)

  • adjuvanted high dose SCB-1019TBiological

    Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)

  • PlaceboOther

    0.9% NaCl saline placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate porportion of participants with solicied AEs of SCB-1019T vaccineTime frame: Within 7 days after vaccination
  2. Evaluate porportions of participants with unsolicited AEs of SCB-1019T vaccineTime frame: Within 28 days after vaccination
  3. Evaluate porportions of participants with SAEs, AESIs, MAAEs, AEs leading to early termination from the study of SCB-1019T vaccineTime frame: Throughout the study period, from enrollment to 6 months follow up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Kids Research Institute

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.